biotech
biotech Articles
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,...
Published:
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. The billionaire is a value investor in the vein of...
Published:
Despite broader market indexes reaching new highs, driven mainly by tech stock momentum, many companies have faced plummeting valuations due to worsening macroeconomic conditions. The market has...
Published:
Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains. An impressive move higher in LLY stock, with the company’s...
Published:
24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease’s progression and reducing fatalities. Wall Street analysts are unanimously bullish on Exact...
Published:
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people...
Published:
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return potential in a...
Published:
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
Published:
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Published:
Here are a few big biopharma names on which Wall Street is growing more bearish.
Published:
A few big biopharma names were on the move Tuesday morning, and analysts were taking their shot at them.
Published:
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Published:
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
Published:
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Published:
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Published: